TPD52 and central nervous system cancer: TPD52, exclusively identified in the R_T0 saliva, was reported as upregulated in the human plasma of high-grade glioma patients and associated with a secondary metastatic group of patients; it should instead be further investigated as a potential biomarker of recurrence.